COYA News

Coya Therapeutics (COYA) was the only company to complete an IPO in the last week of 2022. China-based ASIC chip designer Intchains (ICG) and Hong Kong-based wealth and asset manager Prestige Wealth (PWM) delayed their $29 million and $15 million offerings, respectively. In the pipeline, five companies submitted initial...read more

Coya Therapeutics, a Phase 2 biotech developing regulatory T-cell therapies for various indications, raised $15 million by offering 3.1 million units at $5. Each unit consists of one share of common stock and one warrant to purchase one-half of a share, exercisable at $7.50. ...read more

Coya Therapeutics, a Phase 2 biotech developing regulatory T-cell therapies for various indications, announced terms for its IPO on Monday. The Houston, TX-based company plans to raise $15 million by offering 3.1 million shares at $5. Each share will be sold with one warrant to purchase one-half of a share, exercisable at $7.50. At the proposed price, Coya Therapeutics would...read more

After delaying its offering, Acrivon Therapeutics (ACRV) completed the week’s sole IPO. In the pipeline, seven companies submitted initial filings, including three planning to raise $100 million. Biotech Acrivon Therapeutics (ACRV) offered more shares and priced well below the range to raise $94 million at a $277 million market cap. The...read more